Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

afamitresgene autoleucel

(A-fam-ih-TRES-jeen AW-toh-LOO-sel)
A treatment used for adults with synovial sarcoma that has the MAGE-A4 antigen and has spread to other parts of the body or cannot be removed by surgery. It is used in patients who have certain HLA-A*02 antigens and have received chemotherapy. It is also being studied in the treatment of other types of cancer. Afamitresgene autoleucel is made using a patient’s T cells (a type of immune system cell). A special T-cell receptor that can recognize the MAGE-A4 antigen is added to the T cells in the laboratory. These changed T cells are then grown in large numbers in the laboratory and given back to the patient by infusion. Afamitresgene autoleucel binds to the MAGE-A4 antigen, which is found on some types of cancer cells. This helps the body’s immune system kill cancer cells. Afamitresgene autoleucel is a type of cellular immunotherapy. Also called Tecelra.
More Information
Search NCI's Dictionary of Cancer Terms